Arch Biopartners' AB569 Receives Final Approval from European Commission for Orphan Designation for Cystic Fibrosis
TORONTO, ONTARIO -- (Marketwired) -- 06/01/16 -- Arch Biopartners Inc. (Arch, or the Company) (TSX VENTURE: ACH)(OTCBB: FOIFF), a portfolio based biotechnology company, today announced the European Commission has designated AB569 as an orphan medicinal …